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Abstract
Artichoke leaf extracts are widely used alone or in association with other herbs for embittering alcoholic and soft drinks and
to prepare herbal teas or herbal medicinal products. Despite this wide diffusion, the European Pharmacopoeia does not report
an official method for the determination of the active principles of artichoke leaf extracts.
This work reports a quali-quantitative determination by HPLC/DAD and HPLC/MS techniques of both cynnamic acids and
flavonoids present in some artichoke leaf commercial extracts (Com) compared with two different laboratory extracts (Lab).
Most of the commercial extracts showed a similar quali-quantitative pattern with a single exception having five–six times higher
value. The quantitative data from the Italian Pharmacopoeia(IP) official method does not evaluate the flavonoidic fraction and
showed an overestimation of the caffeoyl esters with respect to the HPLC/DAD results. The proposed HPLC/DAD method
was able to completely characterize and quantify this matrix and represents a contribution to better quality control of these
herbal extracts.
© 2003 Elsevier B.V. All rights reserved.
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1. Introduction
The artichoke (Cynara scolymus L.) is not only a
good food, known for its pleasant bitter taste, but also
an interesting and widespread herbal drug. Artichoke
leaf extracts are widely used alone or in association
with other herbs for embittering alcoholic and soft
drinks and to prepare herbal teas or herbal medici-
nal products. In addition, the use of the dehydrated
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leaf meal in the feeding of young bulls is described
[1]. Polyphenolic compounds, present mainly in the
leaves rather than in the artichoke heads, have been
documented as the active principles of this plant. The
results from several clinical investigations showed
the efficacy and safety of artichoke extracts in the
treatment of hepato-biliary dysfunction and diges-
tive complaints, such as loss of appetite, nausea, and
abdominal pain [2].
Leaf extracts are reported to enhance detoxification
reactions of the liver and have shown cholagogue
and choleretic activity [3–5]. The ability to de-
crease cholesterol levels in the blood by reducing, in
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the liver, the rate of cholesterol synthesis and by
removing fat accumulation from the liver and other
tissues is also described [3,6,8,9]. Findings from
clinical trials have confirmed the anti-hyperlipidemic
effects of artichoke extracts, determining a decrease
of both total cholesterol and LDL-cholesterol levels
[7]. Recently, there is also a growing body of research
which indicates therapeutic properties for artichoke
leaf extract against irritable bowel syndrome (IBS)
[10]. Moreover, a concentration-dependent inhibitory
activity against oxidative stress in human leukocytes,
when these cells are stimulated with agents that gener-
ate reactive oxygen species (ROS), has been observed
[11].
The biological activities of artichoke, mainly the
marked antioxidative effects [5,8,12], are attributed
to caffeoylquinic acid derivatives, and flavonoids
such as luteolin glycosides. Caffeoylquinic acids are
present in artichoke as mono and dicaffeoyl esters
and chlorogenic acid (5-caffeoylquinic acid) with
cynarin (1,3-dicaffeoylquinic acid) and its isomer
(1,5-dicaffeoylquinic acid) are described as the most
abundant molecules [13]. Regarding bioavailability
data, in vivo studies have recently demonstrated that
the caffeoyl esters are adsorbed, metabolized, and
excreted as methylated phenolic acids [14]. Finally, it
is worth noting that scanty data are available in litera-
ture on the chemical characterization of the artichoke
extracts used to carry out biological experiments, not
only for the qualitative aspects but mainly for the
quantitative ones.
Despite the wide diffusion of herbal extracts from
C. scolymus L. leaves, the European Pharmacopoeia
does not report an official method for determination of
the active principles of artichoke till now. An official
determination is described in the tenth edition of the
Italian Pharmacopoeia (IP) where this determination
is made by a spectrophotometric assay at 325 nm after
caffeoylquinic acids precipitation [15].
This work reports a quali-quantitative determi-
nation by HPLC/DAD and HPLC/MS techniques,
both of phenolic acids and flavonoids present in
some artichoke leaf commercial extracts (Com) com-
pared with laboratory extracts (Lab) prepared with
two solvents at different polarity. The quantitative
data from HPLC/DAD and from the Italian Phar-
macopoeia official method are also compared and
discussed.
2. Experimental
2.1. Chemicals and reagents
Methanol and water (HPLC grade) were purchased
from Redel de Haën (Germany); formic acid (ACS
reagent) was from Aldrich Company Inc. (Milwaukee,
Wisconsin); caffeic and chlorogenic acid were ob-
tained from Fluka Chemie AG (Switzerland). Cynarin
(1,3-dicaffeoylquinic acid) was supplied by Roth
(Germany). Caffeoylquinic esters (3-caffeoylquinic
acid, 4-caffeoylquinic acid and an unidentified dicaf-
feoylquinic acid derivative, compounds 3, 4, and 10)
were kindly supplied by Professor Corrado Trogolo,
Università la Sapienza, Roma. The pure flavonoid
compounds, luteolin 7-O-glucoside and luteolin, com-
pounds 8 and 15, were purchased from Extrasynthèse
(Lyon, Nord-Genay, France).
The commercial dry extracts of C. scolymus L.
leaves were purchased from the Italian market and
the dried leaves used for preparation of the laboratory
extracts (Lab1 and Lab2) were obtained from Ulrich
(Nichelino, Torino, Italy).
2.2. Sample preparation
2.2.1. Dried commercial extracts
Four commercial samples were considered (Com1–
4), all purchased from Italian factories working with
herbal products. The samples for analyses were pre-
pared by dissolving about 3 g of powdered extract in
100 ml of MeOH/H2O 1:1, this solution guaranteed the
maximum solubility for all the samples. The solutions
were filtered (0.45m) to obtain Com1, Com2, Com3,
and Com4, and were directly analyzed by HPLC/DAD
and HPLC/MS.
2.2.2. Laboratory extracts
The same batch of dried leaves, purchased from
Ulrich, was used to prepare two different laboratory
extracts. Lab1 was obtained performing an extraction
with water at room temperature, stirring for 10 min,
and applying a laboratory ultrasound bath for 30 min.
The solution was collected after filtration and squeez-
ing of the solid residue, and then lyophilized. Lab2
was obtained mixing the ground dried leaves with
EtOH/H2O 1:1 at 70 ◦C for 10 min under magnetic
stirring, then filtered, concentrated to dryness and then
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dissolved in MeOH/H2O 1:1 with a final concentra-
tion of 3% w/v. These samples were filtered (0.45m)
and directly analyzed by HPLC/DAD and HPLC/MS.
2.3. HPLC/DAD analysis
HPLC/DAD analysis was performed on a Solvent
Delivery System P4000 equipped with a UV600LP
DAD detector and auto sampler AS3000, managed
by a ChromQuest Chromatography data system (all
from ThermoFinnigan, San Jose, CA, USA). The col-
umn was a 3.0 mm × 150 mm (3m) Inertsil ODS-3
(Chrompack, Netherland) equipped with a pre-column
(2.0 mm× 10 mm, 5m) of the same phase; the oven
temperature was 30 ◦C. The eluents were (A): H2O ad-
justed to pH 2.4 by HCOOH and (B): CH3CN. The fol-
lowing concave (type 2) solvent gradient was applied:
from 92% A and 8% B to 30% A and 70% B within
50 min. Flow elution was 0.4 ml min−1 and 2l were
injected for all the samples. Chromatograms were ac-
quired at 326 nm and UV-Vis spectra were recorded
in the range 200–450 nm.
2.4. HPLC/MS analysis
The spectra were registered in negative and posi-
tive ion mode, using two different instrumentations.
The positive MS spectra were performed by an LCQ
electrospray (ThermoFinnigan, San Jose, CA, USA)
directly coupled with the HPLC-DAD (Agilent Tech-
nologies, Palo Alto, CA, USA) applying the same
chromatographic conditions previously described but
with a linear gradient shape. Capillary temperature
was 220 ◦C, capillary voltage 3.0 V, source voltage
4.2 kV, tube lens voltage 30 V and collision energy
35%. Negative MS spectra were also performed by
an API-Electrospray (Agilent Technologies, Palo Alto,
CA, USA) with capillary temperature 350 ◦C and cap-
illary voltage 3500 V; fragmentors applied were in the
range 80–180 V.
2.5. HPLC/DAD quantitative procedure
The method of external standard was applied to
quantify each compound. Quantification of individ-
ual phenols was performed using a five-point regres-
sion curve, each point in duplicate, developed through
the use of authentic standards, operating in the range
0–40g. Measurements were performed at 326 nm for
the caffeoylquinic acid and at 350 nm for the luteolin
derivatives. The following r2 values were obtained:
5-caffeoylquinic acid (chlorogenic acid) and cynar-
inm, r2 = 0.9999; 1,5-dicaffeoylquinic acid, r2 =
0.9998; caffeic acid and luteolin 7-O-glucoside, r2 =
0.9997; luteolin, r2 = 0.9996. The HPLC-DAD quan-
titative data were expressed as milligram per kilogram
for both caffeoylquinic acids and flavonoids deriva-
tives, as average of three determinations.
2.6. Italian Pharmacopoeia method
The procedure described in the Pharmacopoeia X
edition was precisely applied. This determination was
performed by a spectrophotometric assay at 325 nm
after caffeoylquinic acids precipitation with lead ac-
etate and resolubilization with acid methanol. Finally,
the percentages of caffeoylquinic acids are expressed
as chlorogenic acid [15].
3. Results and discussion
This work reports a quali-quantitative evaluation of
the phenolic content of commercial (Com1–4) and
experimental (Lab1–2) artichoke leaf extracts, per-
formed applying both a HPLC/DAD determination on
reverse phase and the official method indicated by the
X edition of the Italian Pharmacopoeia [15].
The identification of each compound was per-
formed by a comparison with available standards and
by UV and MS spectra evaluation. This approach
made it possible to rapidly discriminate between caf-
feoyl derivatives and flavonoidic compounds. The
MS spectra in API/ES negative ionization mode, due
to the low fragmentation level, was strongly diagnos-
tic for the detection of both molecular weight and
the characteristic fragmentation of the cynnamoyl
and flavonoidic molecules [16]. Such results are in
accordance with the findings obtained from the deter-
mination of a fingerprint of a total artichoke extract
by direct infusion in ESI/MS [17].
The main chemical structures of the identified com-
pounds are depicted in Fig. 1, and in Table 1 are listed
the 15 compounds separated with the proposed HPLC
method: four monocaffeoylquinic acid esters, five di-
caffeoylquinic acid esters and five luteolin derivatives.
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Fig. 1. Reference chemical structures of the main compounds: cynarin and luteolin.
A recent study, conducted on artichoke by-products
to recover phenolic fractions with antioxidant activi-
ties, proposed an HPLC method on reverse phase able
to detect only eleven caffeoyl derivatives [18]. There-
fore, no data have been reported about the flavonoidic
content, mainly constituted by luteolin glycosides
[8,19]. Our HPLC method shows the advantages of a
Table 1
List of the identified compounds with their relative retention time (Rt) values
Abbreviations Rt values (min) Compound
1 2 CQ ac 6.67 2-O-Caffeoylquinic acid
2 5 CQ ac 7.97 3-O-Caffeoylquinic acid
3 3 CQ ac 14.65 5-O-Caffeoylquinic acid
4 4 CQ ac 15.5 4-O-Caffeoylquinic acid
5 Caf ac 17.26 Caffeic acid
6 1,5 di CQ ac 22.16 1,5-O-Dicaffeoylquinic acid
7 Lut O-glu 27.09 Luteolin O-monoglucoside
8 Lut7-O-glu 27.98 Luteolin 7-O-glucoside or cynaroside
9 Lut-7-O-rut 28.5 Luteolin 7-O-rutinoside
10 A 29.36 Dicaffeoylquinic acid derivative
11 1,3 di CQ ac 30.18 1,3-O-Dicaffeoylquinic acid
12 Lut 7-O-glr Luteolin 7-O-glucuronide
13 B 29.36 Dicaffeoylquinic acid derivative
14 C 31.36 Dicaffeoylquinic acid derivative
15 Lut 36.67 Luteolin
shorter elution procedure, the use of a more efficient
stationary phase (particle diameter 3m) and the
determination of the flavonoidic content.
The HPLC profiles of three representative extracts
are shown in Fig. 2 with a profile of the caffeoyl deriva-
tives at 326 nm for the richest extract and profiles at
350 nm, respectively, for Com2, Com4, and Lab2.
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For the all considered extracts, the quantitative
HPLC/DAD findings related to the distribution of
each caffeoylquinic ester and flavonoid are summa-
rized in Tables 2 and 3, respectively.
Among all the commercial extracts, only Com2 dif-
fers significantly, appearing largely to be richest in
caffeoyl derivatives, with a total polyphenolic content
around 10% (Fig. 3) and a percent lower amount of
flavonoid with respect to the total dried weight of the
extract. The other three commercial samples, all col-
lected from the Italian market as well, showed a very
similar pattern both in caffeoyl and luteolin deriva-
Fig. 2. HPLC/DAD profiles at (a) 326 nm of Com3 and at 350 nm for (b) Com3, (c) Com4, and (d) Lab2, respectively. The list of numbered
peaks is in Table 1.
tives. It can be concluded that the Com2 sample is ob-
tained by a dedicated multisteps extraction procedure
mainly focused to the enrichment in caffeoyl deriva-
tives, while the other extracts were presumably pre-
pared with similar extractive processes.
To evaluate the influence of the solvent on the total
amount of extracted phenols, two laboratory extracts
were prepared working on the same batch of dried
leaves and applying two different extraction proce-
dures: (1) water at room temperature; (2) EtOH/H2O
1:1 at 70 ◦C. The first procedure was applied because
a recent paper reports data on the biological activity
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Fig. 2. (Continued ).
Fig. 3. Comparison between the total contents of monocaffeoyl derivatives, dicaffeoyl esters, and flavonoids both in Com and Lab
extracts.
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of aqueous artichoke leaf extracts, often with no
or scanty information regarding their composition
[18].
Moreover, hot extraction (70 ◦C) with aqueous
ethanolic solution represents a common approach
to obtain an exhaustive extraction of the phenolic
fraction from raw vegetal material. For both Lab1
and Lab2 extracts, the sums of caffeoyl and lute-
olin derivatives show comparable values to those of
Com1, Com3, and Com4, and remained below 1.3%.
The highest amounts of free caffeic acid and mono-
caffeoyl quinic esters were obtained for the sample
prepared only with water at room temperature (Lab1).
The use of water, compared to EtOH/H2O 1:1 (Lab2),
increases the hydrolysis of dicaffeoyl derivatives
while the aqueous/ethanolic solution, even if working
at 70 ◦C, does not modify the content of dicaffeoyl
derivatives, but, as expected, increases the amount of
flavonoids.
The total amounts of the three main classes of com-
pounds, both in commercial and laboratory extracts
expressed as per cent values, are summarized and com-
pared in the histogram of Fig. 3. With the unique ex-
ception of Com2, the obtained results did not exceed
1.74%. Observing the flavonoidic content, it appeared
mainly constituted by luteolin glycosides with lower
values for the aglycone, which was abundant only in
the Lab1 sample (Table 3).
Finally, a comparison of the findings obtained
from the IP method and HPLC/DAD analysis was
carried out. The percent of caffeoylquinic acids with
IP method is derived from the caffeoylquinic acid
precipitation with lead acetate, dissolution in acid
methanol and, finally, a spectrophotometric determi-
nation at 325 nm, with data expressed as chlorogenic
acid.
As shown in Fig. 4, this complex procedure re-
sulted unable to discriminate among the samples, in
fact, almost the same values were obtained for Lab1,
Lab2, Com1, Com3, and Com4. Moreover, by apply-
ing this procedure, an over-estimation of the results
with respect to the more accurate HPLC/DAD analy-
sis (more then 50%) were obtained for all the extracts.
Finally it does not supply any information about the
flavonoidic content, while this class of compounds
can easily be determined by HPLC/DAD and can
also modulate the biological activity of the artichoke
extracts.
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Table 3
Amounts of flavonoid glycosides in both Com and Lab extracts
7 8 9 15
Lab1 n.d. 1002 ± 21.78 1255 ± 5.29 1170 ± 3.44
Lab2 n.d. 2917 ± 10.57 775 ± 11.00 340 ± 1.08
Com1 1511 ± 17.05 1357 ± 16.43 42 ± 2.12 181 ± 1.25
Com2 788 ± 5.96 1052 ± 18.51 853 ± 13.71 397 ± 0.42
Com3 1584 ± 6.52 1442 ± 2.59 38 ± 0.08 203 ± 1.21
Com4 1553 ± 12.34 1616 ± 14.06 n.d. 127 ± 0.68
Data (mean of three determinations ±S.D.) are expressed in mg/kg of dried extracts, obtained applying the following calibration curves:
luteolin 7-O-glucoside for all the glycosides and the aglycon with luteolin. n.d.: not determined.
Fig. 4. Comparison between total caffeoyl derivatives, obtained by HPLC/DAD and IP determination. The data are expressed as percent
of w/w (dried extracts) applying chlorogenic and caffeic acid calibration curves. Both the mono and dicaffeoylquinic acids are expressed
as sum.
4. Conclusions
The availability of appropriate analytical proce-
dures to investigate the quali-quantitative content of
the active and/or characteristic compounds of herbal
mixtures, used as medicinal herbal products, could
be of relevant interest to guarantee safety, efficacy,
and quality. In light of this consideration, the choice
of a rapid, efficient and accurate method able to
completely characterize and quantify these complex
matrices is one of the main targets in this research
field. This work represents a contribution from this
perspective.
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